Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus placebo in advanced hepatocellular carcinoma
ACTRN12605000644662Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib with Placebo (2 arms). Primary endpoints: Overall survival and Time to symptomatic progression. Started Mar 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ACTRN12605000644662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000644662.